Skip to content

US · GH · MEDICAL - DIAGNOSTICS & RESEARCH

Guardant Health, Inc. (GH) intrinsic value and stock valuation

$145.83as of 2026-11-21 · Mkt cap 22.61B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Guardant Health, Inc. DCF and intrinsic value

InvestorsCraft values GH with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from GH’s statements →

Guardant Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Palo Alto, CA 94304 guardanthealth.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$982M+27.9% 5y CAGRd
20162025
Net income
-$-416.28M
20162025
Free cash flow
-$-233.07M
20162025
Total equity
-$-99.31M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$982M$739M$564M$449.5M$373.7M
Operating income-$-437.25M-$-443.59M-$-564.73M-$-544.38M-$-411M
Net income-$-416.28M-$-436.37M-$-479.45M-$-654.59M-$-405.67M
EPSd-$-3.32M-$-3.55M-$-4.28M-$-6.41M-$-4M
Operating cash flow-$-184.76M-$-239.86M-$-324.98M-$-309.46M-$-209.02M
Capital expenditure-$-48.31M-$-35.09M-$-20.49M-$-77.46M-$-75.03M
Free cash flow-$-233.07M-$-274.94M-$-345.46M-$-386.92M-$-284.05M
Total assets$2.01B$1.49B$1.79B$1.61B$2.2B
Total debt$1.71B$1.34B$1.35B$1.37B$1.37B
Net debt$1.33B$810.5M$220.2M$1.23B$881.5M
Total equity-$-99.31M-$-139.65M$158.7M$60.2M$645M
Cash and short-term investments$1.2B$840M$1.17B$1.01B$932.8M
Income statement
20252024202320222021
Revenue$982M$739M$564M$449.5M$373.7M
Cost of revenue$349M$289.8M$227.1M$156.3M$122.9M
Gross profit$633M$449.2M$336.9M$293.2M$250.7M
Research and development expenses$364.2M$347.8M$367.2M$373.8M$263.2M
Selling, general and administrative expenses$706.1M$545.1M$451M$463.8M$398.5M
Other expenses$0.00$0.00$83.4M$0.00$0.00
Operating expenses$1.07B$892.8M$901.6M$837.6M$661.7M
Cost and expenses$1.42B$1.18B$1.13B$993.9M$784.7M
Interest income$34.1M$53.7M$35.4M$6.07M$3.93M
Interest expense$3.9M$2.58M$2.58M$2.58M$2.58M
Depreciation and amortization$39.7M$42.4M$42.9M$36M$22.3M
Ebitda-$-373.91M-$-390.12M-$-433.31M-$-614.91M-$-359.62M
Operating income-$-437.25M-$-443.59M-$-564.73M-$-544.38M-$-411M
Total other income/expenses, net$19.7M$8.51M$86M-$-109.07M$26.5M
Income before tax-$-417.54M-$-435.09M-$-478.76M-$-653.45M-$-384.47M
Income tax expense-$-1.26M$1.28M$690K$1.14M$300K
Net income-$-416.28M-$-436.37M-$-479.45M-$-654.59M-$-405.67M
Weighted average shares outstanding$125.4M$122.8M$112M$102.2M$101.3M
Weighted average diluted shares outstanding$125.4M$122.8M$112M$102.2M$101.3M
Balance sheet
20252024202320222021
Cash and short-term investments$1.2B$840M$1.17B$1.01B$932.8M
Net receivables$137.9M$110.3M$88.8M$97.3M$97.7M
Inventory$85.9M$71.1M$62M$51.6M$30.7M
Total current assets$1.47B$1.06B$1.35B$1.19B$1.11B
Property, plant and equipment, net$304.8M$279.1M$302.7M$341.9M$313.9M
Goodwill and intangible assets$103.2M$10.1M$12.3M$15M$17.5M
Long-term investments$0.00$0.00$0.00$0.00$698M
Total non-current assets$547.6M$430.5M$439.3M$418.4M$1.09B
Total assets$2.01B$1.49B$1.79B$1.61B$2.2B
Accounts payable$54.4M$38.6M$51.7M$68.9M$38.5M
Short-term debt$27.7M$29.2M$28M$21.9M$12.9M
Deferred revenue$50.8M$35.5M$18M$17.4M$11.3M
Total current liabilities$302.7M$225.6M$205.9M$193.2M$194.7M
Long-term debt$1.68B$1.31B$1.33B$1.35B$1.36B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.81B$1.4B$1.42B$1.36B$1.36B
Capital lease obligations$206.1M$193.5M$213.8M$231.9M$238.9M
Total liabilities$2.11B$1.63B$1.63B$1.55B$1.56B
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-2.99B-$-2.58B-$-2.14B-$-1.66B-$-1.01B
Accumulated other comprehensive income (loss)-$-4.85M-$-5.2M-$-3.67M-$-19.52M-$-4.76M
Total equity-$-99.31M-$-139.65M$158.7M$60.2M$645M
Total investments$823.4M$314.4M$35.1M$869.6M$1.14B
Total debt$1.71B$1.34B$1.35B$1.37B$1.37B
Net debt$1.33B$810.5M$220.2M$1.23B$881.5M
Cash flow statement
20252024202320222021
Net income-$-416.28M-$-436.37M-$-479.45M-$-654.59M-$-384.77M
Depreciation and amortization$39.7M$42.4M$42.9M$36M$22.3M
Stock-based compensation$166.2M$140.4M$90.8M$94.7M$151.5M
Change in working capital-$-14.43M-$-60.86M$53.8M$61.6M-$-40.47M
Accounts receivable-$-28.18M-$-21.39M$8.38M$380K-$-44.35M
Inventory-$-14.79M-$-9.13M-$-10.35M-$-20.93M-$-7.96M
Accounts payable$0.00$0.00$0.00$60.3M$8.64M
Net cash provided by operating activities-$-184.76M-$-239.86M-$-324.98M-$-309.46M-$-209.02M
Investments in property, plant and equipment-$-48.31M-$-35.09M-$-20.49M-$-77.46M-$-75.03M
Acquisitions, net-$-58.99M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-627.2M-$-261.31M$840.3M$149.8M-$-63.16M
Common stock issued$377.8M$14.8M$493.1M$0.00$0.00
Common stock repurchased-$-45.01M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$671.1M-$-1M$477.4M-$-189.09M-$-66.82M
Net change in cash-$-140.34M-$-503.93M$991.7M-$-350.34M-$-340.69M
Cash at end of period$489.4M$629.8M$1.13B$142M$492.3M
Operating cash flow-$-184.76M-$-239.86M-$-324.98M-$-309.46M-$-209.02M
Capital expenditure-$-48.31M-$-35.09M-$-20.49M-$-77.46M-$-75.03M
Free cash flow-$-233.07M-$-274.94M-$-345.46M-$-386.92M-$-284.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Guardant Health, Inc.

        Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

        CEO
        Helmy Eltoukhy
        Employees
        2.51K
        Beta
        1.59

        Explore

        Frequently asked questions

        What is the intrinsic value of Guardant Health, Inc. (GH)?

        Guardant Health, Inc. (GH) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GH undervalued?

        GH trades at a price of $145.83 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.